Management of prolactinoma: a survey of endocrinologists in China

Ji, Lijin; Yi, Na; Zhang, Qi; Zhang, Shuo; Liu, Xiaoxia; Shi, Hongli; Lü, Bin

doi:10.1530/ec-18-0250

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Анкеты охватывали различные аспекты диагностики и лечения пролактином и ГПРЛ [4][5][6][7]. Всего 22-30% респондентов считали, что уровень пролактина (ПРЛ)<2000 мЕд/л исключает наличие пролактиномы.…”

Section: онлайн-опросы по гпрл врачей из разных странunclassified

Hyperprolactinemia in the postmenopause: versions and contraversions

Leshchenko

2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The prevalence of hyperprolactinemia in postmenopausal women is unknown and has been estimated as infrequent by many studies. Prolactinomas found after menopause are usually macroadenomas and remain unrecognized for a long time due to atypical clinical signs or their absence. The growth potential of prolactinomas persists after menopause, most of them are invasive and accompanied by high prolactin levels. Treatment with dopamine agonists is usually long-term, the goals of which are to reduce tumor size, normalize prolactin levels and the negative effects of hyperprolactinemia. Treatment with cabergoline makes it possible to achieve remission of the disease in the first years after discontinuation, however, the proportion of relapses in postmenopausal women increases 5 years after discontinuation of the drug. Remission of prolactinomas is not evident in postmenopausal women. The modern management of patients with prolactinoma and/or hyperprolactinemia does not have clear positions in the postmenopausal period. Controversial issues remain: an ambiguous relationship between prolactin levels and breast cancer, there are no convincing conclusions on the improvement of bone mineral density and/or a decrease in the risk of fractures with normalization of prolactin levels, there are no data on metabolic parameters after the end of treatment with dopamine agonists, conflicting information about the relationship of prolactin levels and the severity of the manifold manifestations of the climacteric syndrome. The use of estrogen-progestin drugs in women with hyperprolactinemia/prolactinomas is also not well understood. Thus, the problem of hyperprolactinemia in the perimenopausal and postmenopausal period is underestimated and requires additional research, as well as the development of diagnostic and therapeutic strategies for potential benefits in terms of weight loss, improving insulin sensitivity, reducing the risk of fractures, maintaining sexuality and psycho-emotional well-being.

show abstract

Section: онлайн-опросы по гпрл врачей из разных странunclassified

Hyperprolactinemia in the postmenopause: versions and contraversions

Leshchenko

2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

“…Table 1 lists the studies (n = 19) that were excluded along with the reason for exclusion [ Table 1 ]. [ 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ] Finally, eight (n = 8) studies were included in this scoping review. [ 34 35 36 37 38 39 40 41 ] Characteristics of all the studies[ 34 35 36 37 38 39 40 41 ] are shown in Table 2 .…”

Section: R Esultsmentioning

confidence: 99%

A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas

Mishra¹,

Konar²,

Shrivastava³

et al. 2021

Indian Journal of Endocrinology and Metabolism

View full text Add to dashboard Cite

Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. However, there is contradicting and inadequate evidence on the efficacy of cabergoline in achieving radiological and biochemical remission in prolactinoma. This article presents scoping review of evidence in cabergoline achieving radiological and biochemical remission in cases of prolactinoma. We have used a recommended scoping review methodology to map and summarize existing research evidence and identify knowledge gaps. The review process was conducted according to the PRISMA-ScR guidelines (Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews). The selection of studies was based on the criteria defined. Essential information such as reference details, study characteristics, topics of interest, main findings, and the study author's conclusion are presented in text and tables. With the study selection process, eight publications were finally included—one systematic review and meta-analysis, one RCT, and six primary studies. Cabergoline is effective in achieving biochemical and radiological remission in cases of prolactinoma. We identified several knowledge gaps with the scoping review and directions for future studies. Future studies, including randomized studies, will help address challenging questions associated with the management of prolactinoma.

show abstract